Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albendazole plus praziquantel versus albendazole alone for active parenchymal neurocysticercosis
PACTR202402822223203Phase 4Recruiting
- Sponsor
- Revolution Worldwide
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of albendazole and praziquantel in neurocysticercosis (NCC) (2 arms), sponsored by Revolution Worldwide. Primary endpoint: Cyst resolution or reduction. Started May 2024; status: recruiting.
02
Drugs
albendazolepraziquantel
03
Conditions
neurocysticercosis (NCC)
Beyond the preview
Go deeper on PACTR202402822223203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402822223203.